AUG 13, 2026 · PHASE 1/2 TRIAL
A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer
ClinicalTrials.gov
Early-phase dose-finding study (Phase 1/2) with very small enrollment (9 participants) and no results reported; designed to establish safety and MTD before efficacy testing.
Reported
Sample size9
Phase 1 primary outcomeMaximum tolerated dose (MTD) at 1 year
Phase 2 primary outcomeProgression-free survival at 12 months